Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Bonnet, Fabrice"" wg kryterium: Autor


Tytuł :
ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study).
Autorzy :
Fleury H; Pole de Biologie, CHU de Bordeaux, 33076 Bordeaux, France.; CNRS UMR 5234, Université de Bordeaux, 33076 Bordeaux, France.
Caldato S; Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, CHU de Bordeaux et Université de Bordeaux, ISPED INSERM U 1219, 33076 Bordeaux, France.
Recordon-Pinson P; CNRS UMR 5234, Université de Bordeaux, 33076 Bordeaux, France.
Thebault P; Laboratoire Bordelais de Recherche en Informatique (LaBri), Université de Bordeaux, 33400 Talence, France.
Guidicelli GL; Laboratoire d'Immunologie et Immunogénétique, CHU de Bordeaux, 33076 Bordeaux, France.
Hessamfar M; Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, CHU de Bordeaux et Université de Bordeaux, ISPED INSERM U 1219, 33076 Bordeaux, France.
Morlat P; Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, CHU de Bordeaux et Université de Bordeaux, ISPED INSERM U 1219, 33076 Bordeaux, France.
Bonnet F; Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, CHU de Bordeaux et Université de Bordeaux, ISPED INSERM U 1219, 33076 Bordeaux, France.
Visentin J; Laboratoire d'Immunologie et Immunogénétique, CHU de Bordeaux, 33076 Bordeaux, France.; CNRS Immuno ConcEpT, Université de Bordeaux, UMR 5164, 33076 Bordeaux, France.
Pokaż więcej
Źródło :
Viruses [Viruses] 2020 Nov 05; Vol. 12 (11). Date of Electronic Publication: 2020 Nov 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adaptive Immunity*
AIDS Vaccines/*immunology
Epitopes, T-Lymphocyte/*immunology
HIV Infections/*therapy
HIV-1/*immunology
Peptides/*immunology
AIDS Vaccines/therapeutic use ; Alleles ; CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/immunology ; Chronic Disease/therapy ; HIV Infections/immunology ; HIV Seropositivity ; HIV-1/drug effects ; HLA-A Antigens/genetics ; HLA-A Antigens/immunology ; HLA-B Antigens/genetics ; HLA-B Antigens/immunology ; Humans ; Peptides/chemistry ; Programmed Cell Death 1 Receptor/genetics ; Programmed Cell Death 1 Receptor/immunology
Czasopismo naukowe
Tytuł :
Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohort's QuAliV ancillary study.
Autorzy :
Barger D; Univ Bordeaux, ISPED, Inserm Bordeaux Population Health, team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000, Bordeaux, France. .
Hessamfar M; Univ Bordeaux, ISPED, Inserm Bordeaux Population Health, team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000, Bordeaux, France.; Services de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire de Bordeaux (CHU), F-33000, Bordeaux, France.; COREVIH Nouvelle Aquitaine, Bordeaux, France.
Neau D; Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Bordeaux (CHU), F-33000, Bordeaux, France.
Vareil MO; Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Bordeaux (CHU), F-33000, Bordeaux, France.; Service de maladies infectieuses, Centre Hospitalier de la Côte Basque, F-64100, Bayonne, France.
Lazaro E; Services de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire de Bordeaux (CHU), F-33000, Bordeaux, France.
Duffau P; Services de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire de Bordeaux (CHU), F-33000, Bordeaux, France.; UMR-5164 CNRS, CIRID, University of Bordeaux, F-33000, Bordeaux, France.
Rouanes N; Centre Hospitalier de de Périgueux, F-24000, Périgueux, France.
Leleux O; Univ Bordeaux, ISPED, Inserm Bordeaux Population Health, team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000, Bordeaux, France.
Le Marec F; Univ Bordeaux, ISPED, Inserm Bordeaux Population Health, team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000, Bordeaux, France.
Erramouspe M; AIDES Nouvelle Aquitaine, Bordeaux, France.
Wittkop L; Univ Bordeaux, ISPED, Inserm Bordeaux Population Health, team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000, Bordeaux, France.; Pôle de Santé Publique, Centre Hospitalier Universitaire de Bordeaux (CHU), F-33000, Bordeaux, France.
Dabis F; Univ Bordeaux, ISPED, Inserm Bordeaux Population Health, team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000, Bordeaux, France.; COREVIH Nouvelle Aquitaine, Bordeaux, France.; Pôle de Santé Publique, Centre Hospitalier Universitaire de Bordeaux (CHU), F-33000, Bordeaux, France.
Bonnet F; Univ Bordeaux, ISPED, Inserm Bordeaux Population Health, team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000, Bordeaux, France.; Services de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire de Bordeaux (CHU), F-33000, Bordeaux, France.; COREVIH Nouvelle Aquitaine, Bordeaux, France.
Pokaż więcej
Źródło :
Health and quality of life outcomes [Health Qual Life Outcomes] 2020 Jul 10; Vol. 18 (1), pp. 220. Date of Electronic Publication: 2020 Jul 10.
Typ publikacji :
Journal Article; Validation Study
MeSH Terms :
Quality of Life*
HIV Infections/*psychology
Surveys and Questionnaires/*standards
Cross-Sectional Studies ; Factor Analysis, Statistical ; Female ; France ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Prospective Studies ; Psychometrics/instrumentation ; Reproducibility of Results ; Translations
Czasopismo naukowe
Tytuł :
Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV.
Autorzy :
Besson C; Hematology-Oncology Unit, Centre Hospitalier de Versailles, Le Chesnay.; Université Versailles Saint Quentin en Yvelines, Université Paris-Saclay, Communauté Paris-Saclay; Centre for Research in Epidemiology and Population Health (CESP) INSERM Unit 1018, Villejuif.
Noel N; INSERM U1184, Centre for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin-Bicêtre; Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre, AP-HP, Hôpitaux Paris Sud, Internal Medicine Unit, Le Kremlin-Bicêtre.
Lancar R; Sorbonne Universités, INSERM, UPMC Université Paris 06, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS1136), Paris.
Prevot S; AP-HP, Hôpitaux Paris Sud Site Béclère, Pathology Unit, Clamart.
Algarte-Genin M; Internal medicine unit, CHU l'Archet, Nice.
Rosenthal E; Internal medicine unit, CHU l'Archet, Nice.
Bonnet F; CHU Bordeaux, Internal Medicine and Infectious Diseases Unit, and INSERM U1219, Université de Bordeaux, Bordeaux.
Meyohas MC; AP-HP CHU Saint-Antoine, Infectious Diseases Unit, Paris.
Partisani M; Hôpitaux Universitaires, HIV Infection Unit, Strasbourg.
Oberic L; Toulouse III Paul Sabatier University, U1037, CRCT, Department of Haematology, Institut Universitaire du Cancer (IUC), Toulouse.
Gabarre J; AP-HP CHU Pitié-Salpêtrière, Department of Haematology, Paris.
Goujard C; INSERM U1184, Centre for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin-Bicêtre; Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre, AP-HP, Hôpitaux Paris Sud, Internal Medicine Unit, Le Kremlin-Bicêtre.
Cheret A; Infectious diseases Unit, Hôpital de Tourcoing, Tourcoing.
Arvieux C; Infectious Diseases Unit, CHU de Rennes, Rennes.
Katlama C; Infectious Diseases Unit, Hôpital La Pitié-Salpêtrière.
Salmon D; Infectious Diseases Unit, Hôpital Cochin, Paris.
Boué F; Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre, AP-HP, Hôpitaux Paris Sud Site Béclère, Clinical Immunology Unit, Clamart.
Costello R; Department of Hematology, AP-HM, Assistance Publique Hôpitaux de Marseille, Marseille.
Hendel-Chavez H; INSERM U1184, Centre for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin-Bicêtre, Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre; AP-HP, Hôpitaux Paris Sud, Immunology Unit, Le Kremlin-Bicêtre.
Taoufik Y; INSERM U1184, Centre for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin-Bicêtre, Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre; AP-HP, Hôpitaux Paris Sud, Immunology Unit, Le Kremlin-Bicêtre.
Fontaine H; Hepatology unit, Hôpital Cochin.
Coppo P; Department of Hematology, AP-HP CHU Saint-Antoine, Paris.
Mounier N; Department of Onco-Hematology, Archet Hospital, Nice.
Delobel P; Infectious Diseases Unit, CHU Toulouse, Toulouse, France.
Costagliola D; Sorbonne Universités, INSERM, UPMC Université Paris 06, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS1136), Paris.
Pokaż więcej
Corporate Authors :
Lymphovir and FHDH study groups
Źródło :
AIDS (London, England) [AIDS] 2020 Mar 15; Vol. 34 (4), pp. 599-608.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
HIV Infections/*complications
Hepatitis B, Chronic/*complications
Hepatitis C, Chronic/*complications
Lymphoma, AIDS-Related/*complications
Adult ; Aged ; Aged, 80 and over ; Coinfection ; Databases, Factual ; Female ; France ; Hepatitis B, Chronic/epidemiology ; Hepatitis C, Chronic/epidemiology ; Humans ; Lymphoma, AIDS-Related/mortality ; Male ; Middle Aged ; Prevalence ; Prospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Cervical cancer risk in women living with HIV across four continents: A multicohort study.
Autorzy :
Rohner E; Institute of Social and Preventive Medicine, University of Bern, Switzerland.
Bütikofer L; CTU Bern, University of Bern, Switzerland.
Schmidlin K; Institute of Social and Preventive Medicine, University of Bern, Switzerland.
Sengayi M; National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa.
Maskew M; Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Giddy J; Department of Medicine, McCord Hospital, Durban, South Africa.
Taghavi K; Institute of Social and Preventive Medicine, University of Bern, Switzerland.
Moore RD; Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Goedert JJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Gill MJ; University of Calgary, Alberta, Canada.
Silverberg MJ; Division of Research, Kaiser Permanente Northern California, Oakland, USA.
D'Souza G; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Patel P; Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia.
Castilho JL; Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, USA.
Ross J; TREAT Asia/amfAR - The Foundation for AIDS Research, Bangkok, Thailand.
Sohn A; TREAT Asia/amfAR - The Foundation for AIDS Research, Bangkok, Thailand.
Bani-Sadr F; Reims Champagne-Ardenne University, Faculté de médecine, CHU Reims, Hôpital Robert Debré, Tropical and Infectious Diseases, Reims, France.
Taylor N; IIIrd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectious Diseases and Rheumathology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.
Paparizos V; AIDS Unit, Clinic of Venereologic and Dermatologic Diseases, Athens Medical School, 'Syngros' Hospital, Athens, Greece.
Bonnet F; CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint-André, Bordeaux, France.; Univ. Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health, F-33000 Bordeaux, France.
Verbon A; Department Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands.
Vehreschild JJ; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.; German Centre for Infection Research, partner site Bonn-Cologne, Cologne, Germany.
Post FA; King's College Hospital NHS Foundation Trust, London, UK.
Sabin C; Institute for Global Health, UCL, London, United Kingdom.
Mocroft A; Institute for Global Health, UCL, London, United Kingdom.
Dronda F; Department of Infectious Diseases, Hospital Ramón y Cajal, Madrid, Spain.
Obel N; Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark.
Grabar S; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F-75013, Paris, France.; INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F-75013, Paris, France.; Université Paris Descartes et Assistance Publique-Hôpitaux de Paris, Groupe hospitalier Cochin Hôtel-Dieu, Paris, France.
Spagnuolo V; Vita-Salute San Raffaele University, Faculty of Medicine and Surgery, Milan, Italy.
Quiros-Roldan E; Infectious and Tropical Diseases Institute, University of Brescia, Brescia, Italy.
Mussini C; Infectious Diseases Clinics, University Hospital, Modena, Italy.
Miro JM; Infectious Diseases Service, Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain.
Meyer L; INSERM, U1018, Epidemiology of HIV, Reproduction, Paediatrics, CESP, University Paris-Sud, Paris, France.; Department of Public Health and Epidemiology, Bicêtre Hospital, AP-HP, Le Kremlin Bicêtre, Paris, France.
Hasse B; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland.
Konopnicki D; Department of Infectious Diseases, St Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Roca B; Hospital General Universitario, Castellón, Spain.
Barger D; Univ. Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health, F-33000 Bordeaux, France.
Clifford GM; International Agency for Research on Cancer, Lyon, France.
Franceschi S; Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Egger M; Institute of Social and Preventive Medicine, University of Bern, Switzerland.; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa.
Bohlius J; Institute of Social and Preventive Medicine, University of Bern, Switzerland.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2020 Feb 01; Vol. 146 (3), pp. 601-609. Date of Electronic Publication: 2019 Jun 19.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
MeSH Terms :
Health Status Disparities*
HIV Infections/*complications
Uterine Cervical Neoplasms/*epidemiology
Adolescent ; Adult ; Age Factors ; Anti-Retroviral Agents/therapeutic use ; CD4 Lymphocyte Count ; Cross-Cultural Comparison ; Early Detection of Cancer ; Europe/epidemiology ; Female ; Follow-Up Studies ; HIV Infections/blood ; HIV Infections/drug therapy ; Humans ; Incidence ; Latin America/epidemiology ; Middle Aged ; North America/epidemiology ; Risk Factors ; South Africa/epidemiology ; Uterine Cervical Neoplasms/complications ; Uterine Cervical Neoplasms/prevention & control ; Young Adult
Czasopismo naukowe
Tytuł :
Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings.
Autorzy :
Trickey A; aPopulation Health Sciences, University of Bristol, Bristol, UK bStichting HIV Monitoring, Amsterdam, The Netherlands cAvenir Health, Glastonbury, Connecticut, USA dDepartment of Internal Medicine, Antoine Béclère Hospital, Clamart eUniversity of Paris Saclay, Paris-Sud University, UVSQ fCESP INSERM U1018, Le Kremlin-Bicêtre gSorbonne Université, INSERM, Institut Pierre Louis d'épidemiologie et de Santé Publique (IPLESP), Unité de Biostatistique et d'épidémiologie Groupe hospitalier Cochin Broca Hôtel-Dieu, Assistance Publique Hôpitaux de Paris (AP-HP), and Université Paris Descartes, Sorbonne Paris Cité, Paris hUniversity of Bordeaux, ISPED, INSERM U1219 and CHU de Bordeaux, Bordeaux, France iHospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain jFirst Department of Internal Medicine, University of Cologne, Cologne, Germany kCEEISCAT/Agència de Salut Pública de Catalunya, Campus Can Ruti and CIBERESP, Badalona, Catalonia, Spain lClinic of Infectious and Tropical Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy mService of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland nNational Epidemiology Center, Carlos III Health Institute, Madrid, Spain and National Plan on AIDS, Ministry of Health, Madrid, Spain oInnsbruck Medical University, Austria pDivision of Infectious Diseases, University of Calgary, Calgary, Canada qDepartment of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark.
van Sighem A
Stover J
Abgrall S
Grabar S
Bonnet F
Berenguer J
Wyen C
Casabona J
d'Arminio Monforte A
Cavassini M
Del Amo J
Zangerle R
Gill MJ
Obel N
Sterne JAC
May MT
Pokaż więcej
Źródło :
AIDS (London, England) [AIDS] 2019 Dec 15; Vol. 33 Suppl 3, pp. S271-S281.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Developed Countries*
HIV Infections/*drug therapy
HIV Infections/*mortality
Adult ; Anti-HIV Agents/therapeutic use ; Cohort Studies ; Europe/epidemiology ; Female ; Humans ; Male ; Middle Aged ; Models, Statistical ; Mortality/trends ; Risk Factors
Czasopismo naukowe
Tytuł :
Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals.
Autorzy :
Caniglia EC; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Department of Population Health, School of Medicine, New York University, New York, New York.
Robins JM; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Cain LE; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Sabin C; University College London, London, UK.
Logan R; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Abgrall S; APHP Hôpital Avicenne, Bobigny, France.
Mugavero MJ; School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Hernández-Díaz S; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Meyer L; Inserm, Université Paris Sud, Orsay, France.
Seng R; Inserm, Université Paris Sud, Orsay, France.
Drozd DR; University of Washington, Seattle, Washington.
Seage Iii GR; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Bonnet F; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
Le Marec F; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
Moore RD; School of Medicine, The Johns Hopkins University, Baltimore, Maryland.
Reiss P; Academisch Medisch Centrum Geneeskunde, Amsterdam, The Netherlands.
van Sighem A; Academisch Medisch Centrum Geneeskunde, Amsterdam, The Netherlands.
Mathews WC; Department of Medicine, University of California San Diego Health, San Diego, California.
Jarrín I; National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
Alejos B; National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
Deeks SG; School of Medicine, University of California, San Francisco, San Francisco, California.
Muga R; Germans Trias Hospital, Barcelona, Spain.
Boswell SL; Fenway Health, Boston, Massachusetts.
Ferrer E; Hospital Universitari de Bellvitge, Barcelona, Spain.
Eron JJ; Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Gill J; Southern Alberta HIV Program, Calgary, Canada.
Pacheco A; Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Grinsztejn B; Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Napravnik S; Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Jose S; University College London, London, UK.
Phillips A; University College London, London, UK.
Justice A; School of Public Health, Yale University, New Haven, Connecticut.
Tate J; School of Public Health, Yale University, New Haven, Connecticut.
Bucher HC; Universitätsspital Basel, Basel, Switzerland.
Egger M; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Furrer H; Division of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Miro JM; University of Barcelona, Barcelona, Spain.
Casabona J; Institut Català d'Oncologia, Barcelona, Spain.
Porter K; University College London, London, UK.
Touloumi G; Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Athens, Greece.
Crane H; University of Washington, Seattle, Washington.
Costagliola D; University Pierre and Marie Curie, Paris, France.
Saag M; University of Alabama at Birmingham, Birmingham, Alabama.
Hernán MA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts.
Pokaż więcej
Źródło :
Statistics in medicine [Stat Med] 2019 Jun 15; Vol. 38 (13), pp. 2428-2446. Date of Electronic Publication: 2019 Mar 18.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-HIV Agents/*administration & dosage
Drug Monitoring/*statistics & numerical data
HIV Infections/*drug therapy
Adult ; CD4 Lymphocyte Count ; Decision Making ; Female ; HIV Infections/mortality ; Humans ; Male ; Middle Aged ; RNA, Viral/analysis ; Research Design ; Survival Analysis ; Viral Load
Czasopismo naukowe
Tytuł :
Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era.
Autorzy :
Lupo J; Institut de Biologie Structurale (IBS), CEA, CNRS, Université Grenoble-Alpes.
Germi R; Institut de Biologie Structurale (IBS), CEA, CNRS, Université Grenoble-Alpes.
Lancar R; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP).
Algarte-Genin M; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP).
Hendel-Chavez H; AP-HP, Hôpitaux Paris Sud, Service d'Immunologie biologique.
Taoufik Y; INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases Université Paris Sud.
Mounier N; Département d'Hémato-Oncologie, Archet Hospital, Nice.
Partisani M; Hôpitaux Universitaires, Centre de soins de l'infection VIH, Strasbourg.
Bonnet F; CHU Bordeaux, Service de Médecine Interne et Maladies Infectieuses.
Meyohas MC; AP-HP CHU Saint-Antoine, Service de maladies infectieuses, Paris.
Marchou B; CHU Toulouse, Service de maladies infectieuses, Toulouse.
Semanova T; Institut de Biologie Structurale (IBS), CEA, CNRS, Université Grenoble-Alpes.
Prevot S; AP-HP, Hôpitaux Paris Sud Site Béclère, Service d'anatomo-pathologie.
Costagliola D; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP).
Morand P; Institut de Biologie Structurale (IBS), CEA, CNRS, Université Grenoble-Alpes.
Besson C; INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre Unité d'Hémato-Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France.
Pokaż więcej
Źródło :
AIDS (London, England) [AIDS] 2019 May 01; Vol. 33 (6), pp. 993-1000.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Viral/*blood
Biomarkers/*blood
DNA, Viral/*blood
Epstein-Barr Virus Infections/*complications
HIV Infections/*complications
Herpesvirus 4, Human/*isolation & purification
Hodgkin Disease/*diagnosis
Adult ; Anti-Retroviral Agents/therapeutic use ; Female ; HIV Infections/drug therapy ; Herpesvirus 4, Human/genetics ; Herpesvirus 4, Human/immunology ; Humans ; Male ; Prognosis ; Prospective Studies ; Viral Load
Czasopismo naukowe
Tytuł :
Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles.
Autorzy :
Tumiotto C; University Hospital of Bordeaux, CNRS UMR 5234, Bordeaux, France.
Alves BM; Instituto Nacional de Cancer, Rio de Janeiro, Brazil.
Recordon-Pinson P; University Hospital of Bordeaux, CNRS UMR 5234, Bordeaux, France.
Jourdain M; University Hospital of Bordeaux, CNRS UMR 5234, Bordeaux, France.
Bellecave P; University Hospital of Bordeaux, CNRS UMR 5234, Bordeaux, France.
Guidicelli GL; University Hospital of Bordeaux, CNRS UMR 5234, Bordeaux, France.
Visentin J; University Hospital of Bordeaux, CNRS UMR 5234, Bordeaux, France.
Bonnet F; University Hospital of Bordeaux, CNRS UMR 5234, Bordeaux, France.
Hessamfar M; University Hospital of Bordeaux, CNRS UMR 5234, Bordeaux, France.
Neau D; University Hospital of Bordeaux, CNRS UMR 5234, Bordeaux, France.
Sanchez J; Centro de Investigationes Technologicas, Biomedicas y Madioambiantales, Lima, Peru.
Brander C; IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias I Pujol, Badalona, Spain.; Central University of Catalonia, Barcelona, Spain.; ICREA, Barcelona, Spain.
Sajadi M; Institute of Human Virology, Baltimore, MD, United States of America.
Eyzaguirre L; Institute of Human Virology, Baltimore, MD, United States of America.
Soares EA; Instituto Nacional de Cancer, Rio de Janeiro, Brazil.
Routy JP; McGill University Health Centre, Montreal, Quebec, Canada.
Soares MA; Instituto Nacional de Cancer, Rio de Janeiro, Brazil.
Fleury H; University Hospital of Bordeaux, CNRS UMR 5234, Bordeaux, France.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2019 Feb 27; Vol. 14 (2), pp. e0212347. Date of Electronic Publication: 2019 Feb 27 (Print Publication: 2019).
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Design*
DNA, Viral/*genetics
Epitopes, T-Lymphocyte/*immunology
HIV Infections/*prevention & control
HIV-1/*immunology
HLA Antigens/*immunology
T-Lymphocytes, Cytotoxic/*immunology
Viral Vaccines/*immunology
Alleles ; Antigen Presentation ; Cohort Studies ; HIV Infections/immunology ; HIV Infections/virology ; HIV-1/genetics ; Humans ; Viral Vaccines/administration & dosage ; Viral Vaccines/genetics
Czasopismo naukowe
Tytuł :
Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.
Autorzy :
Shepherd L; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, United Kingdom.
Ryom L; Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Section, Rigshospitalet, University of Copenhagen, Denmark.
Law M; Kirby Institute, University of New South Wales, Sydney, Australia.
Petoumenos K; Kirby Institute, University of New South Wales, Sydney, Australia.
Hatleberg CI; Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Section, Rigshospitalet, University of Copenhagen, Denmark.
d'Arminio Monforte A; Dipartimento di Scienze della Salute, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy.
Sabin C; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, United Kingdom.
Bower M; National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, United Kingdom.
Bonnet F; Centre Hospitalier Universitaire de Bordeaux and Institut National de la Santé et de la Recherche Médicale, Université de Bordeaux, France.
Reiss P; Academic Medical Center, Department of Global Health and Division of Infectious Diseases, University of Amsterdam.; HIV Monitoring Foundation, Amsterdam, The Netherlands.
de Wit S; Division of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Pradier C; Department of Public Health, Nice University Hospital, France.
Weber R; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland.
El-Sadr W; ICAP-Columbia University and Harlem Hospital, New York, New York.
Lundgren J; Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Section, Rigshospitalet, University of Copenhagen, Denmark.
Mocroft A; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, United Kingdom.
Pokaż więcej
Corporate Authors :
Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group
Źródło :
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2019 Feb 01; Vol. 68 (4), pp. 650-657.
Typ publikacji :
Journal Article
MeSH Terms :
HIV Infections/*complications
Neoplasms/*epidemiology
Neoplasms/*prevention & control
Smoking Cessation/*statistics & numerical data
Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Prospective Studies
Czasopismo naukowe
Tytuł :
A New HIV-1 Circulating Recombinant Form (CRF98_cpx) Between CRF06_cpx and Subtype B Identified in Southwestern France.
Autorzy :
Recordon-Pinson P; 1 CNRS MFP-UMR 5234 , Bordeaux, France .
Alves BM; 2 National Institute of Cancer , Rio de Janeiro, Brazil .
Tumiotto C; 1 CNRS MFP-UMR 5234 , Bordeaux, France .; 3 Department of Biology and Pathology, University Hospital of Bordeaux , Bordeaux, France .
Bellecave P; 3 Department of Biology and Pathology, University Hospital of Bordeaux , Bordeaux, France .
Bonnet F; 4 Department of Internal Medicine, University Hospital of Bordeaux , Bordeaux, France .
Neau D; 5 Department of Infectious and Tropical Diseases, University Hospital of Bordeaux , Bordeaux, France .
Soares EA; 2 National Institute of Cancer , Rio de Janeiro, Brazil .
Soares MA; 2 National Institute of Cancer , Rio de Janeiro, Brazil .
Fleury H; 1 CNRS MFP-UMR 5234 , Bordeaux, France .; 3 Department of Biology and Pathology, University Hospital of Bordeaux , Bordeaux, France .
Pokaż więcej
Źródło :
AIDS research and human retroviruses [AIDS Res Hum Retroviruses] 2018 Nov; Vol. 34 (11), pp. 1005-1009. Date of Electronic Publication: 2018 Aug 23.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Phylogeny*
HIV Infections/*virology
HIV-1/*classification
HIV-1/*genetics
Adult ; CD4 Lymphocyte Count ; DNA, Viral/genetics ; France/epidemiology ; Genome, Viral/genetics ; Genotype ; HIV Infections/epidemiology ; HIV-1/isolation & purification ; Humans ; Male ; Middle Aged ; Recombination, Genetic ; Sequence Analysis, DNA ; Seroconversion ; Viral Load ; Viral Proteins/genetics
Czasopismo naukowe
Tytuł :
Costs associated with hospitalization in HIV-positive patients in France.
Autorzy :
de Léotoing L; HEVA, Lyon.
Yazdanpanah Y; Hôpital Bichat-Claude-Bernard, Paris.
Finkielsztejn L; ViiV Healthcare, Rueil-Malmaison.
Chaize G; HEVA, Lyon.
Vainchtock A; HEVA, Lyon.
Nachbaur G; GlaxoSmithKline, Rueil-Malmaison.
Aubin C; ViiV Healthcare, Rueil-Malmaison.
Bonnet F; CHU de Bordeaux.; INSERM U1219 Université de Bordeaux, Bordeaux, France.
Pokaż więcej
Źródło :
AIDS (London, England) [AIDS] 2018 Sep 10; Vol. 32 (14), pp. 2059-2066.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
HIV Infections/*complications
Health Care Costs/*statistics & numerical data
Hospitalization/*economics
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Animals ; Child ; Child, Preschool ; Female ; France ; Humans ; Infant ; Infant, Newborn ; Male ; Middle Aged ; Retrospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Associations between serum albumin and serious non-AIDS events among people living with HIV.
Autorzy :
Ronit A; Department of Infectious Diseases.
Hatleberg CI; CHIP, Department of Infectious Diseases, University of Copenhagen, Copenhagen, Denmark.
Ryom L; CHIP, Department of Infectious Diseases, University of Copenhagen, Copenhagen, Denmark.
Bonnet F; CHU de Bordeaux and INSERM U1219, Université de Bordeaux, Talence, France.
El-Sadr W; ICAP at Columbia University, New York, New York, USA.
Reiss P; Academic Medical Center, Department of Global Health and Division of Infectious Diseases, University of Amsterdam, and HIV Monitoring Foundation, Amsterdam, The Netherlands.
Weber R; Department of Infectious diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Pradier C; Department of Public Health, Nice University Hospital, Nice, France.
De Wit S; Division of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Law M; The Kirby Institute, UNSW Australia, Sydney, Australia.
d'Arminio Monforte A; Dipartimento di Scienze della Salute, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy.
Lundgren J; CHIP, Department of Infectious Diseases, University of Copenhagen, Copenhagen, Denmark.
Mocroft A; Institute for Global Health, UCL, London, UK.
Phillips AN; Institute for Global Health, UCL, London, UK.
Sabin CA; Institute for Global Health, UCL, London, UK.
Pokaż więcej
Corporate Authors :
D:A:D Study Group
Źródło :
AIDS (London, England) [AIDS] 2018 Aug 24; Vol. 32 (13), pp. 1837-1848.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Cardiovascular Diseases/*epidemiology
End Stage Liver Disease/*epidemiology
HIV Infections/*complications
Kidney Failure, Chronic/*epidemiology
Neoplasms/*epidemiology
Serum Albumin, Human/*analysis
Adult ; Female ; Follow-Up Studies ; Humans ; Male ; Prospective Studies ; Risk Assessment ; Survival Analysis
Czasopismo naukowe
Tytuł :
Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D: A: D Cohort Analysis.
Autorzy :
Achhra AC; The Kirby Institute, UNSW Australia, Sydney, Australia.; Internal Medicine, New York Presbyterian/Weill Cornell Medical Center, New York, NY.
Sabin C; Institute for Global Health, UCL, London, United Kingdom.
Ryom L; CHIP, Department of Infectious Diseases, Section 2100, 2Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Hatleberg C; CHIP, Department of Infectious Diseases, Section 2100, 2Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Antonella dʼAminio M; Dipartimento di Scienze della Salute, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy.
de Wit S; Division of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Phillips A; Institute for Global Health, UCL, London, United Kingdom.
Pradier C; Department of Public Health, Nice University Hospital, Nice, France.
Weber R; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland.
Reiss P; Division of Infectious Diseases, Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.; HIV Monitoring Foundation, Amsterdam, the Netherlands.
El-Sadr W; ICAP-Columbia University and Harlem Hospital, New York, NY.
Bonnet F; ISPED, INSERM U1219, CHU de Bordeaux, Université de Bordeaux, Bordeaux, France.
Mocroft A; Institute for Global Health, UCL, London, United Kingdom.
Lundgren J; CHIP, Department of Infectious Diseases, Section 2100, 2Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Law MG; The Kirby Institute, UNSW Australia, Sydney, Australia.
Pokaż więcej
Corporate Authors :
D:A:D Study Group
Źródło :
Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2018 Aug 15; Vol. 78 (5), pp. 579-588.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
MeSH Terms :
Body Mass Index*
Cause of Death*
Cardiovascular Diseases/*complications
Diabetes Mellitus/*mortality
HIV Infections/*mortality
HIV Infections/*physiopathology
Neoplasms/*complications
Adult ; Cardiovascular Diseases/mortality ; Cohort Studies ; Female ; HIV Infections/complications ; Humans ; Male ; Middle Aged ; Neoplasms/mortality ; Poisson Distribution
Czasopismo naukowe
Tytuł :
Multimorbidity, age-related comorbidities and mortality: association of activation, senescence and inflammation markers in HIV adults.
Autorzy :
Duffau P; CNRS-UMR 5164, Immuno ConcEpT, Bordeaux University and Bordeaux Hospital.; CHU de Bordeaux, Service de Médecine Interne et Immunologie Clinique.
Ozanne A; University Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401.
Bonnet F; University Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401.; CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint-André, Bordeaux.
Lazaro E; CNRS-UMR 5164, Immuno ConcEpT, Bordeaux University and Bordeaux Hospital.; CHU de Bordeaux, Service de Médecine Interne et Maladies infectieuses, Hôpital Haut-Lévêque, Pessac.
Cazanave C; CHU de Bordeaux, Service de Maladies Infectieuses et Tropicales.
Blanco P; CNRS-UMR 5164, Immuno ConcEpT, Bordeaux University and Bordeaux Hospital.; CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, University Bordeaux.
Rivière E; CHU de Bordeaux, Service de Médecine Interne et Maladies infectieuses, Hôpital Haut-Lévêque, Pessac.
Desclaux A; CHU de Bordeaux, Service de Maladies Infectieuses et Tropicales.
Hyernard C; CNRS-UMR 5164, Immuno ConcEpT, Bordeaux University and Bordeaux Hospital.
Gensous N; CHU de Bordeaux, Service de Médecine Interne et Immunologie Clinique.
Pellegrin I; University Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401.; CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, University Bordeaux.
Wittkop L; University Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401.; CHU de Bordeaux, Pôle de santé publique, Bordeaux, France.
Pokaż więcej
Źródło :
AIDS (London, England) [AIDS] 2018 Jul 31; Vol. 32 (12), pp. 1651-1660.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Aging*
Mortality*
Multimorbidity*
HIV Infections/*complications
HIV Infections/*pathology
Inflammation/*pathology
Adult ; Female ; Humans ; Male ; Middle Aged ; Prevalence ; Risk Assessment ; Survival Analysis ; Viral Load
Czasopismo naukowe
Tytuł :
HIV is associated with airway obstruction: a matched controlled study.
Autorzy :
Makinson A; Infectious and Tropical Diseases Department, University Hospital Montpellier.; UMI 233/INSERMU1175, IRD, University Montpellier.
Hayot M; Department of Clinical Physiology, INSERM U-1046, University Hospital Montpellier 1, University of Montpellier, Montpellier.
Eymard-Duvernay S; Infectious and Tropical Diseases Department, University Hospital Montpellier.
Ribet C; UMS 11 INSERM-UVSQ, 'Cohortes épidémiologiques en Population', Villejuif.
Raffi F; CIC 1413, INSERM, University Hospital, Nantes.
Pialoux G; Infectious and Tropical Diseases Department, University Hospital Tenon, UPMC, Paris.
Zucman D; HIV Department, AP-HP, Foch Hospital Suresnes, Suresnes.
Poizot-Martin I; Immuno-Hematology Clinic, APHM Sainte-Marguerite Hospital, Aix-Marseille University/SESSTIM, Marseille.
Bonnet F; Internal Medicine and Infectious Diseases Department, INSERM U1219, University Hospital Bordeaux, Bordeaux.
Abgrall S; Department of Internal Medicine, AP-HP, Antoine Béclère Hospital, Clamart.
Tattevin P; Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes.
Cheret A; Infectious Diseases Department, Tourcoing Hospital, Tourcoing.
Ferry T; University Hospital de la Croix Rousse, Lyon.
Mauboussin JM; Infectious and Tropical Diseases Unit, Nîmes University Hospital, Nîmes.
Marchand L; France Recherche Nord et Sud Sida-HIV et Hépatites.
Rouzaud C; Department of Infectious Diseases and Tropical Medicine, Infectiology Centre Necker-Pasteur, AP-HP, Necker-Enfants Malades Hospital, Paris, France.
Reynes J; Infectious and Tropical Diseases Department, University Hospital Montpellier.; UMI 233/INSERMU1175, IRD, University Montpellier.
Zins M; UMS 11 INSERM-UVSQ, 'Cohortes épidémiologiques en Population', Villejuif.
Le Moing V; Infectious and Tropical Diseases Department, University Hospital Montpellier.; UMI 233/INSERMU1175, IRD, University Montpellier.
Pokaż więcej
Corporate Authors :
ANRS EP48 HIV CHEST study Team
Źródło :
AIDS (London, England) [AIDS] 2018 Jan 14; Vol. 32 (2), pp. 227-232.
Typ publikacji :
Journal Article
MeSH Terms :
HIV Infections/*complications
Pulmonary Disease, Chronic Obstructive/*epidemiology
Smoking/*adverse effects
Adolescent ; Adult ; Age Factors ; Aged ; Case-Control Studies ; Female ; Humans ; Male ; Middle Aged ; Pilot Projects ; Young Adult
Czasopismo naukowe
Tytuł :
Abacavir use and risk of recurrent myocardial infarction.
Autorzy :
Sabin CA; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, Royal Free Campus, University College London, London, UK.
Ryom L; CHIP, Department of Infectious Diseases Section 2100, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
d'Arminio Monforte A; Dipartimento di Scienze della Salute, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy.
Hatleberg CI; CHIP, Department of Infectious Diseases Section 2100, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Pradier C; Department of Public Health, Nice University Hospital, Nice, France.
El-Sadr W; ICAP-Columbia University and Harlem Hospital, New York, NY, USA.
Kirk O; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, Royal Free Campus, University College London, London, UK.
Weber R; Division of infectious diseases and hospital epidemiology, University hospital Zurich, University of Zurich, Zurich, Switzerland.
Phillips AN; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, Royal Free Campus, University College London, London, UK.
Mocroft A; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, Royal Free Campus, University College London, London, UK.
Bonnet F; CHU de Bordeaux and INSERM U897, Université de Bordeaux, Talence, France.
Law M; Kirby Institute, UNSW Sydney, Sydney, Australia.
de Wit S; Division of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Reiss P; Academic Medical Center, Department of Global Health and Div. of Infectious Diseases, University of Amsterdam, and HIV Monitoring Foundation, Amsterdam, The Netherlands.
Lundgren JD; CHIP, Department of Infectious Diseases Section 2100, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Pokaż więcej
Corporate Authors :
D:A:D Study Group
Źródło :
AIDS (London, England) [AIDS] 2018 Jan 02; Vol. 32 (1), pp. 79-88.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Anti-HIV Agents/*adverse effects
Anti-HIV Agents/*therapeutic use
Dideoxynucleosides/*adverse effects
Dideoxynucleosides/*therapeutic use
HIV Infections/*complications
HIV Infections/*drug therapy
Myocardial Infarction/*epidemiology
Female ; Humans ; Male ; Middle Aged ; Recurrence ; Risk Assessment
Czasopismo naukowe
Tytuł :
Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.
Autorzy :
Besson C; aUnit of Hematology-Oncology, Centre Hospitalier de Versailles, Le ChesnaybUniversité Versailles Saint Quentin en Yvelines, Université Paris-Saclay, Communauté Paris-Saclay, PariscINSERM U1018, Centre pour la Recherche en Epidémiologie et Santé des Populations (CESP), Equipe 'Générations et Santé' Gustave Roussy, VillejuifdSorbonne Universités, INSERM, UPMC Univ Paris 06, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS1136), PariseUniversité Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-BicêtrefPathology Unit, AP-HP, Hôpitaux Paris Sud Site Béclère, ClamartgInfectious Diseases Unit, CHU Toulouse, ToulousehInternal Medicine and Infectious Diseases Unit, CHU Bordeaux, INSERM U1219, Université de Bordeaux, BordeauxiInfectious Diseases Unit, AP-HP CHU Saint-Antoine, ParisjHIV Infection Unit, Hôpitaux Universitaires, StrasbourgkU1037, CRCT, University Toulouse III Paul SabatierlDepartment of Hematology, Institut Universitaire du Cancer (IUC), ToulousemDepartment of Hematology, AP-HP, CHU Pitié-Salpétrière, ParisnInternal Medicine Unit, AP-HP, Hôpitaux Paris Sud, Le Kremlin-BicêtreoClinical Immunology Unit, AP-HP, Hôpitaux Paris Sud Site Béclère, ClamartpDepartment of Hematology, AP-HP CHU Saint-Antoine, ParisqDepartment of Hematology, AP-HM, Assistance Publique Hôpitaux de Marseille, MarseillerImmunology Unit, AP-HP, Hôpitaux Paris Sud, Le Kremlin-BicêtresDepartment of Hematology, AP-HP, Hôpital Necker Enfants Malades, ParistHematology Unit, Centre Hospitalier Universitaire-Dijon, DijonuDepartment of Onco-Hematology, Archet Hospital, Nice, France.
Lancar R
Prevot S
Algarte-Genin M
Delobel P
Bonnet F
Meyohas MC
Partisani M
Oberic L
Gabarre J
Goujard C
Boue F
Coppo P
Costello R
Hendel-Chavez H
Mekerri N
Dos Santos G
Recher C
Delarue R
Casasnovas RO
Taoufik Y
Mounier N
Costagliola D
Pokaż więcej
Corporate Authors :
ANRS-CO16 LYMPHOVIR Cohort
Źródło :
AIDS (London, England) [AIDS] 2017 Nov 28; Vol. 31 (18), pp. 2493-2501.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-Retroviral Agents/*therapeutic use
Antineoplastic Agents/*therapeutic use
HIV Infections/*complications
HIV Infections/*drug therapy
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Female ; France ; Humans ; Lymphoma, Large B-Cell, Diffuse/mortality ; Male ; Middle Aged ; Prospective Studies ; Survival Analysis ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients.
Autorzy :
Thiébaut R; aBordeaux University, INSERM U1219, Bordeaux Population Health Research Center, INRIA Sistm bCentre Hospitalier Universitaire de Bordeaux, Bordeaux cINSERM U955, Paris Est Créteil University dGroupe Hospitalier Henri-Mondor Albert-Chenevier, Créteil, France. *Rodolphe Thiébaut and Sophie Hue cocontributing authors.
Hue S
Le Marec F
Lelièvre JD
Dupon M
Foucat E
Lazaro E
Dabis F
Duffau P
Wittkop L
Surenaud M
Pellegrin I
Lacabaratz C
Bonnet F
Lévy Y
Pokaż więcej
Corporate Authors :
ANRS CO3 Aquitaine Cohort
Źródło :
AIDS (London, England) [AIDS] 2017 Nov 13; Vol. 31 (17), pp. 2355-2365.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers/*blood
HIV Infections/*mortality
Interleukin-1 Receptor-Like 1 Protein/*blood
Serum/*chemistry
Adult ; Female ; Humans ; Interleukin-6/blood ; Lipopolysaccharide Receptors/blood ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Risk Assessment ; Survival Analysis
Czasopismo naukowe
Tytuł :
High decay of blood HIV reservoir when tenofovir/emtricitabine/elvitegravir/cobicistat is initiated during the acute primary HIV infection.
Autorzy :
Ngo Bell EC; CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, 33000 Bordeaux, France.
Vandenhende MA; CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, 33000 Bordeaux, France.
Caldato S; CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, 33000 Bordeaux, France.
Saunier A; CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, 33000 Bordeaux, France.
Bellecave P; CHU de Bordeaux, Laboratoire de Virologie, Hôpital Pellegrin, 33000 Bordeaux, France.
Tumiotto C; CHU de Bordeaux, Laboratoire de Virologie, Hôpital Pellegrin, 33000 Bordeaux, France.
Avettand-Fenoel V; APHP Hôpital Necker-Enfants Malades, Laboratoire de Virologie, Paris, France.; Université Paris-Descartes Sorbonne Paris Cité, Faculté de Médecine, EA 7327, Paris, France.
Hessamfar M; CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, 33000 Bordeaux, France.
Morlat P; CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, 33000 Bordeaux, France.
Bonnet F; CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, 33000 Bordeaux, France.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2017 Sep 01; Vol. 72 (9), pp. 2681-2683.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Anti-HIV Agents/*administration & dosage
Cobicistat/*administration & dosage
Emtricitabine/*administration & dosage
HIV Infections/*drug therapy
HIV-1/*isolation & purification
Quinolones/*administration & dosage
Tenofovir/*administration & dosage
Adult ; Blood/virology ; HIV Infections/virology ; Humans ; Male ; Middle Aged ; Secondary Prevention/methods ; Treatment Outcome ; Viral Load
Czasopismo naukowe
Tytuł :
Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.
Autorzy :
Caniglia EC; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA. Electronic address: .
Cain LE; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
Sabin CA; University College London, London, UK.
Robins JM; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA; Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA.
Logan R; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
Abgrall S; Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Antoine Béclère, Service de Médecine Interne, Clamart, France.
Mugavero MJ; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; UAB Center for AIDS Research, University of Alabama at Birmingham, Birmingham, AL, USA.
Hernández-Díaz S; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
Meyer L; Université Paris Sud, INSERM CESP U1018, Paris, France; AP-HP, Hopital de Bicêtre, Service de Santé Publique, le Kremlin Bicêtre, France.
Seng R; Université Paris Sud, INSERM CESP U1018, Paris, France; AP-HP, Hopital de Bicêtre, Service de Santé Publique, le Kremlin Bicêtre, France.
Drozd DR; School of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Seage GR 3rd; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
Bonnet F; Institut de Santé Publique, d'Epidémiologie et de Développement, Université de Bordeaux, Bordeaux, France; Department of Internal Medicine, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
Dabis F; INSERM U897, Centre INSERM Epidémiologie et Biostatistique, Université de Bordeaux, Bordeaux, France; Department of Internal Medicine, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
Moore RD; School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Reiss P; Stichting HIV Monitoring, Amsterdam, Netherlands; Academic Medical Center, Department of Global Health and Division of Infectious Diseases, University of Amsterdam, Amsterdam, Netherlands; Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands.
van Sighem A; Stichting HIV Monitoring, Amsterdam, Netherlands.
Mathews WC; Internal Medicine, Johns Hopkins University, Baltimore, MD, USA.
Del Amo J; National Centre of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain; Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Moreno S; Ramón y Cajal Hospital, IRYCIS, Madrid, Spain; University of Alcalá de Henares, Madrid, Spain.
Deeks SG; Positive Health Program, San Francisco General Hospital, San Francisco, CA, USA.
Muga R; Servei de Medicina Interna, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain.
Boswell SL; Fenway Health, Boston, MA, USA.
Ferrer E; Hospital Universitari de Bellvitge-Bellvitge Institute for Biomedical Research, Hospitalet de Llobregat, Barcelona, Spain.
Eron JJ; Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Napravnik S; Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jose S; University College London, London, UK.
Phillips A; University College London, London, UK.
Justice AC; Yale School of Medicine, New Haven, CT, USA; VA Connecticut Healthcare System, West Haven, CT, USA.
Tate JP; Yale School of Medicine, New Haven, CT, USA; VA Connecticut Healthcare System, West Haven, CT, USA.
Gill J; Southern Alberta HIV Clinic, University of Calgary, Calgary, AB, Canada.
Pacheco A; Programa de Computação Científica, FIOCRUZ, Rio de Janeiro, Brazil.
Veloso VG; Programa de Computação Científica, FIOCRUZ, Rio de Janeiro, Brazil.
Bucher HC; Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland.
Egger M; Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland.
Furrer H; Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland.
Porter K; University College London, London, UK.
Touloumi G; Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Athens, Greece.
Crane H; Department of Medicine, University of Washington, Seattle, WA, USA.
Miro JM; Infectious Diseases, Hospital Clinic-IDIBAPS, Barcelona, Spain.
Sterne JA; School of Social and Community Medicine, University of Bristol, Bristol, UK.
Costagliola D; Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
Saag M; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Hernán MA; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA; Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA.
Pokaż więcej
Corporate Authors :
HIV-CAUSAL Collaboration
Centers for AIDS Research Network of Integrated Clinical Systems
Źródło :
The lancet. HIV [Lancet HIV] 2017 Jun; Vol. 4 (6), pp. e251-e259. Date of Electronic Publication: 2017 Apr 11.
Typ publikacji :
Comparative Study; Journal Article; Observational Study; Research Support, N.I.H., Extramural
MeSH Terms :
Drug Monitoring/*methods
HIV Infections/*drug therapy
Adolescent ; Adult ; Anti-HIV Agents/economics ; Anti-HIV Agents/therapeutic use ; CD4 Lymphocyte Count ; Developed Countries ; Drug Monitoring/economics ; Europe ; Female ; HIV Infections/blood ; HIV Infections/economics ; HIV Infections/virology ; HIV-1/drug effects ; HIV-1/genetics ; HIV-1/isolation & purification ; HIV-1/physiology ; Humans ; Male ; Middle Aged ; Prospective Studies ; Viral Load ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies